Andrei Iagaru
15
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
6.7%
1 terminated/withdrawn out of 15 trials
91.7%
+5.2% vs industry average
0%
0 trials in Phase 3/4
109%
12 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Role: lead
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Role: lead
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Role: lead
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Role: lead
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Role: lead
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Role: lead
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Role: lead
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
Role: lead
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Role: lead
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Role: lead
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Role: lead
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
Role: lead
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Role: lead
18F-FSPG PET/CT for Cancer Patients on Therapy
Role: lead
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Role: lead
All 15 trials loaded